Overview

GLS4/RTV and TAF Drug-drug Interaction

Status:
Completed

Trial end date:
2021-03-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Sunshine Lake Pharma Co., Ltd.

Treatments:

Ritonavir
Tenofovir